Ludwig Hantson - 15 Jul 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: Director
Issuer ticker: IONS
Reported as of: 15 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jul 2026, 17:13:10 UTC
Prior SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: By: Patrick R. O'Neil, attorney-in-fact For: Ludwig Hantson

Key filing fact

Ludwig Hantson filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 17 Jul 2026.

Key facts

This page summarizes Ludwig Hantson's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Jul 2026, 17:13.

Change

Previous filing in this sequence was filed on 08 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001491435 Primary reporting owner

HANTSON LUDWIG

Relationship: Director
Address: 2855 GAZELLE COURT, CARLSBAD
Signature: By: Patrick R. O'Neil, attorney-in-fact For: Ludwig Hantson
Signature date: 17 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IONS transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +3,399
Change %
Price: $0.000000^*
Shares after: 3,399
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,399
Exercise price: $0.000000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

Footnote F2

Grant on July 15, 2026 to reporting person of Restricted Stock Unit Award under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in three equal annual installments, the first installment vesting on July 15, 2027. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on July 15, 2029. The RSU is vested as to 0 shares on July 15, 2026.